SCHEDULE 13G: Investment Funds Disclose 9.9% Stake in Scinai Immunotherapeutics via Standby Equity Purchase Agreement

YA II PN, Ltd. and its affiliates have disclosed a 9.9% beneficial ownership stake in Scinai Immunotherapeutics Ltd. through a Standby Equity Purchase Agreement, allowing the company to sell up to $10 million in ADSs.

Summary

• YA II PN, Ltd. and its affiliates, including YA Global Investments II (U.S.), LP, Yorkville Advisors Global, LP, Yorkville Advisors Global II, LLC, YAII GP, LP, YAII GP II, LLC, Mark Angelo, and SC-Sigma Global Partners, LP, have filed a Schedule 13G.
• These reporting persons collectively beneficially own 93,274 American Depository Shares (ADSs) of Scinai Immunotherapeutics Ltd.
• This ownership represents 9.9% of the outstanding ADSs, calculated based on 933,679 ADSs reported by Scinai as of March 11, 2025.
• The beneficial ownership stems from a Standby Equity Purchase Agreement (SEPA) entered into between YA II PN, Ltd. and Scinai Immunotherapeutics Ltd. on March 3, 2025.
• Under the SEPA, Scinai has the option to sell up to $10 million of its ADSs to YA II PN, Ltd., and YA II PN, Ltd. is obligated to purchase these shares at a price and on terms specified in the agreement.
• A key condition of the SEPA prohibits Scinai from issuing and selling shares to YA II PN, Ltd. if it would cause the aggregate number of ADSs beneficially owned by YA II PN, Ltd. and its affiliates to exceed 9.99% of Scinai's then outstanding ADSs.

Sentiment

Score: 6

Explanation: The filing itself is a routine disclosure of a significant ownership stake and a financing agreement. While the SEPA provides a funding mechanism (positive), it also carries the risk of dilution for existing shareholders, which is a common trade-off for companies needing capital. The 9.9% stake is a compliance trigger, not necessarily an endorsement of the company's immediate prospects, but the commitment to purchase up to $10M is a positive for liquidity.

Positives

• Provides Scinai Immunotherapeutics Ltd. with a potential source of capital up to $10 million through the Standby Equity Purchase Agreement (SEPA).
• The SEPA obligates YA II PN, Ltd. to purchase shares when Scinai exercises its option, offering a committed funding mechanism.

Negatives

• The SEPA is an 'at-the-market' type facility, meaning shares will be sold at prevailing market prices, which could lead to dilution for existing shareholders if the stock price is low.
• The 9.99% beneficial ownership cap for YA II PN, Ltd. and its affiliates limits the total amount of capital that can be raised through this specific agreement if the company's market capitalization is low.

Risks

• Potential for significant shareholder dilution if Scinai Immunotherapeutics Ltd. exercises its option to sell ADSs under the SEPA, especially if the share price declines.
• The actual amount of capital raised depends on Scinai's decision to exercise the option and the prevailing market price of its ADSs.
• The 9.99% beneficial ownership cap could restrict the full utilization of the $10 million facility if the company's market capitalization is small relative to the facility size.

Future Outlook

The Standby Equity Purchase Agreement provides Scinai Immunotherapeutics Ltd. with a flexible mechanism to raise up to $10 million in capital by selling American Depository Shares to YA II PN, Ltd. at market prices, subject to a 9.99% beneficial ownership cap.

Industry Context

This type of Standby Equity Purchase Agreement (SEPA) is a common financing tool for smaller public companies, particularly in capital-intensive sectors like biotechnology, to secure access to capital on an 'as-needed' basis. It provides flexibility but can also lead to dilution if shares are issued at lower market prices. The 9.99% cap is typical to avoid triggering certain beneficial ownership reporting requirements or change of control provisions.

Stakeholder Impact

• Shareholders: Potential for dilution if Scinai exercises its option to sell ADSs under the SEPA, as new shares will be issued. However, it also provides a funding source which could support company operations and development.
• Company (Scinai Immunotherapeutics Ltd.): Gains access to a flexible capital raising facility of up to $10 million, which can be crucial for funding operations, research, and development in the biotechnology sector.

Next Steps

• Scinai Immunotherapeutics Ltd. may choose to exercise its option to sell ADSs to YA II PN, Ltd. under the Standby Equity Purchase Agreement to raise capital.
• YA II PN, Ltd. will continue to monitor its beneficial ownership percentage relative to the 9.99% cap as shares are potentially issued.

Key Dates

Recommendation

Keywords

Scinai Immunotherapeutics, YA II PN Ltd, Standby Equity Purchase Agreement, SEPA, ADSs, American Depository Shares, Equity Financing, Capital Raise, SEC Filing, Schedule 13G, Biotechnology, Immunotherapeutics, Investment, Dilution